IntelGenx (OTC: IGXT) is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company’s unique multiple layer delivery system provides zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx’ development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. For more information, visit the company’s website at www.intelgenx.com